Avanos Medical Highlights Strategic Transformation Initiatives
TipRanks (Mon, 13-Jan 11:27 AM ET)
Avanos Medical, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRNewswire (Mon, 6-Jan 8:54 AM ET)
Avanos Medical, Inc. to Present at the Stifel 2024 Healthcare Conference
PRNewswire (Tue, 12-Nov 12:08 PM ET)
PRNewswire (Mon, 11-Nov 9:39 AM ET)
Avanos Medical, Inc. to Present at the UBS Healthcare Conference 2024
PRNewswire (Fri, 8-Nov 4:17 PM ET)
Avanos Medical Launches New CORGRIP SR
PRNewswire (Tue, 5-Nov 7:00 AM ET)
Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO
PRNewswire (Wed, 30-Oct 6:45 AM ET)
Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
PRNewswire (Wed, 23-Oct 6:20 AM ET)
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
Avanos Medical trades on the NYSE stock market under the symbol AVNS.
As of January 15, 2025, AVNS stock price declined to $15.82 with 56,140 million shares trading.
AVNS has a beta of 1.01, meaning it tends to be more sensitive to market movements. AVNS has a correlation of 0.13 to the broad based SPY ETF.
AVNS has a market cap of $727.04 million. This is considered a Small Cap stock.
Last quarter Avanos Medical reported $170 million in Revenue and $.36 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.01.
In the last 3 years, AVNS traded as high as $35.91 and as low as $14.98.
The top ETF exchange traded funds that AVNS belongs to (by Net Assets): IJR, VTI, VB, IWM, VBR.
AVNS has underperformed the market in the last year with a price return of -18.9% while the SPY ETF gained +25.6%. AVNS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.2% and -0.6%, respectively, while the SPY returned +1.6% and +0.9%, respectively.
AVNS support price is $15.46 and resistance is $16.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVNS shares will trade within this expected range on the day.